Similar higher anti‐tumor efficacy results were obtained when lexatumumab (or KMTR2) was used either in combination of anti‐PD‐L1 avelumab antibody (Fig 5M–P) or a PD‐1 inhibitor (Fig EV4C and D). This evidence concerns the gene CD274 and neoplasm.